VYNE Therapeutics Inc. (VYNE) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts VYNE Hot Sheet
Join SI Premium – FREE
VYNE Therapeutics Inc. (NASDAQ: VYNE) reported Q3 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $133.33 thousand.
For earnings history and earnings-related data on VYNE Therapeutics Inc. (VYNE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applovin shares surge on strong Q3 results and guidance
- Wolfspeed (WOLF) Misses Q1 EPS by 147c; Offers Guidance
- Murphy Oil (MUR) Tops Q3 EPS by 34c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
